Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?

Figures & data

Table 1.  COPD intervention trials of clinical importance referenced by the GOLD strategy

Reference	Exacerbation Type - Mild, Moderate, Severe	Exacerbation Endpoint - Primary, Secondary, Exploratory	Comparators	Difference In Exacerbation Rate	Statistically Significant - Yes/No
39	All	Secondary	Salmeterol/placebo	25%	Yes
40	All	Secondary	Salmeterol (two doses)/placebo	14%	No
41	Moderate	Secondary	Formoterol/placebo	50%	Yes*
41	Moderate	Secondary	Theophylline/placebo	37.5%	Yes*
42	All	Secondary	Indacaterol/placebo	30.5%	Yes
43	All	Secondary	Tiotropium/ipratropium	7.4%	No
44	All	Secondary	Tiotropium/ipratropium	24%	Yes
45	All	Secondary	Tiotropium/placebo	14%	Yes
46	All	Secondary	Tiotropium/placebo	14%	Yes
31	All	Primary	Tiotropium/salmeterol	11%	Yes
38	All	Secondary	Theophylline/placebo	53.5%	Yes
47	All	Secondary	Fluticasone/placebo	25%	Yes
39	Moderate, severe	Secondary	Salmeterol and fluticasone/placebo	25%	Yes
39	Moderate, severe	Secondary	Salmeterol and fluticasone/salmeterol	12%	Yes
39	Moderate, severe	Secondary	Salmeterol and fluticasone/fluticasone	9%	Yes
39	Moderate, severe	Secondary	Salmeterol/placebo	15%	Yes
39	Moderate, severe	Secondary	Fluticasone/placebo	18%	Yes
48	All	Secondary	Salmeterol and fluticasone/placebo	25%	Yes
48	All	Secondary	Salmeterol/placebo	20%	Yes
48	All	Secondary	Fluticasone/placebo	19%	Yes
49	All	Secondary	Fluticasone/placebo (completing trial)	6%	No
49	All	Secondary	Fluticasone/placebo (not completing trial)	41%	Yes
50	Severe	Secondary	Budesonide + Formoterol/placebo	24%	Yes
36	Moderate, severe	Primary	Roflumilast/Placebo	17%	Yes

*Number of days.